Contact
searchSearch
HMP Global

MCL/CLL Specialty Channel Specialty Channel

Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma
Specialty Channel
Inhye Ahn, MD
Videos
Investigating Next Steps for Pirtobrutinib Therapy Among Patients With Chronic Lymphocytic Leukemia
07/28/2024
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
Novel Developments in the Frontline and Relapsed/Refractory Mantle Cell Lymphoma Treatment Landscape
07/28/2024
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
Exploring Non-Chemotherapy Options for the Frontline Treatment of Patients With Mantle Cell Lymphoma
07/28/2024
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates &...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
Michael Wang, MD
Videos
Ibrutinib Plus Venetoclax Demonstrates Efficacy, Safety for TP53-Mutated Mantle Cell Lymphoma Treatment
07/09/2024
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Michael Wang, MD, presents data...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Quiz
Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma
07/09/2024
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...
True or False: According to a...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Use of BTK Inhibitors in the First-Line Mantle Cell Lymphoma Treatment Landscape
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, provides insight into the use of BTK inhibitors in the frontline mantle cell lymphoma treatment space.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Advances in Chemoimmunotherapy for Frontline Mantle Cell Lymphoma Treatment
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Nicole Lamanna, MD
Conference Coverage
Exploring Potential Options for Treating Patients With Chronic Lymphocytic Leukemia With Pirtobrutinib
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network

In the News

News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
Venetoclax-Ibrutinib Demonstrates Long-Term Efficacy Among Patients With R/R Mantle Cell Lymphoma
09/05/2024
Combination venetoclax-ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma demonstrated durable responses and an acceptable toxicity profile, according to 7-year outcomes from the AIM clinical trial.
Combination venetoclax-ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma demonstrated durable responses and an acceptable toxicity profile, according to 7-year outcomes from the AIM clinical trial.
Combination venetoclax-ibrutinib...
09/05/2024
Lymphoma, Leukemia & Myeloma Network
News
Reduction of Specialized Follow-Ups for Patients With Asymptomatic and Low-to-Intermediate Risk CLL
09/04/2024
Study results demonstrated feasibility and safety among a subset of patients with chronic lymphocytic leukemia (CLL) who have low-to-intermediate risk CLL International Prognostic Index and CLL without need of treatment scores who ended...
Study results demonstrated feasibility and safety among a subset of patients with chronic lymphocytic leukemia (CLL) who have low-to-intermediate risk CLL International Prognostic Index and CLL without need of treatment scores who ended...
Study results demonstrated...
09/04/2024
Lymphoma, Leukemia & Myeloma Network
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma
06/26/2023
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and...
06/26/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use